Published: 2022-04-27

Reaching the one billion mark: accomplishing the success story of COVID vaccination through public interrogation

Avir Sarkar, Kallol Kumar Roy, Rinchen Zangmo, Aarthi K. Jayraj, Durga Kaushik, Rakhi Rai


Background: The COVID vaccination drive in India has recently crossed the one billion mark which is certainly a tremendous feat. Although women were initially hesitant, public propaganda and behaviour change communications encouraged them to come forward. The aim of the study was to assess the vaccination status of female population of the country through interrogation in obstetrics and gynaecology out patient departments (OBG OPD).

Methods: Through this cross-sectional study, all women visiting OBG OPD were asked about type and number of vaccine doses received, dates of administration of first and second doses and whether they had any significant side effects following immunization.

Results: A total of 1456 women were recruited in the study. Mean age of participants was 33.24±4.65 years. 36.26% participants were pregnant. 89.97% women had received at least one dose of vaccine and 48.76% participants were fully vaccinated. Majority received Covishield vaccine. Majority of the participants received first shot during the months of July, August and September. No women suffered from any adverse effect following immunization. Most women got motivated for vaccination from television (76.91%) and alert messages in mobile phones (61.59%). The results of our study reflects the success story of vaccination campaign as almost 90% of the participants had received at least one dose of vaccine.

Conclusions: The proactive participation and untiring efforts of the frontline workers has been instrumental in achieving this remarkable landmark. India's successful vaccination campaign is a lesson to the world at large.


SARS-CoV-2, Vaccination, Coronavirus disease

Full Text:



Ministry of Health and Family Welfare. COVID-19 Vaccine Operational Guidelines. Ministry of Health and Family Welfare, Government of India, 2020. Available at: Accessed on 12 November 2021.

Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol. 2020;11:586781.

Zeev N, Kochhar S. Expecting the unexpected with COVID-19 vaccines. Lancet Infect Dis. 2021;21(2):150-1.

ICMR. Vaccine information, ICMR, New Delhi - COVID-19 vaccine, 2021. Available at: Accessed on 12 November 2021.

Kumar VM, Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines. 2021;6(1):60.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-32.